Academic Strategic Plan

May 24, 2018

Seven interdisciplinary programs land TIPs awards for 2018

Vanderbilt University’s transformational Trans-Institutional Programs initiative heads into a fourth year with grants awarded to seven interdisciplinary projects that involve more than 60 faculty members.

L-r: Eric Johnson, Björn Knollmann, Dai Chung, Dan Roden, Russell Rothman, Susan Wente, Carrie Kitko, Dane Chetkovich, Rangaraj Ramanujam, Timothy Vogus, Berk Sensoy and Jeff Balser. (John Russell/Vanderbilt)
March 5, 2018

Nine new endowed chair recipients honored

Nine Vanderbilt University faculty members named to endowed chairs were honored during a celebration at the Student Life Center Feb. 28.

March 5, 2018

Faculty can learn more about internal funding, resources at March 22 event

More than 15 programs, including internal funding initiatives and professional development opportunities, will be showcased March 22 at the Faculty Funding and Resource Fair.

November 20, 2017

15 faculty members elected as AAAS fellows

Fifteen Vanderbilt faculty members conducting a range of biomedical and clinical research have been elected fellows of the American Association for the Advancement of Science. Six of the 15 have received funding through the university’s Trans-Institutional Programs initiative, which facilitates research and teaching collaborations across disciplines and are a core pillar of the university’s Academic Strategic Plan.

L-r: Maria Magdalena Campos-Pons, Heather Conner, Donna Y. Ford, Rhonda Y. Williams, D. Borden Lacy, Erik William Carter, Jeffrey L. Neul, Kevin M. Stack, Atsushi Inoue, Jonathan G. Schoenecker, Joni Hersch and Provost Susan R. Wente at the Oct. 23 endowed chair celebration. (John Russell/Vanderbilt)
October 25, 2017

Celebration honors 11 university endowed chair holders

Eleven Vanderbilt University faculty members named to endowed chairs were honored Oct. 23 during a festive celebration at the Student Life Center.

elderly Asian mother and adult daughter
August 7, 2017

Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.